Valerian for Anxiety Relief
Valerian's anxiolytic effect has been understood as a parallel pharmacology to its sedative-hypnotic effect since the German Commission E monograph of 1985, which recognized it for "restlessness and nervous tension" alongside its sleep indication. The clinical evidence base is thinner than for sleep — the foundational paper is Andreatini's 2002 randomized controlled trial in generalized anxiety disorder, with a handful of supporting trials of valerian in pre-procedural anxiety and stress-induced sympathetic activation. The mechanism is now understood: valerenic acid is a positive allosteric modulator at the gamma-aminobutyric acid-A receptor at a site distinct from the benzodiazepine-binding site, producing a benzodiazepine-like calming effect that is described as slower to build (1-2 weeks of consistent dosing), with no dependence, tolerance, or withdrawal reported in its trials (two case reports of delirium after valerian root was stopped are described below). This positions valerian not as a competitor to alprazolam or lorazepam for acute panic attacks (where it has no role) but as a tolerable adjunct for chronic generalized anxiety in patients seeking to avoid prescription benzodiazepines, particularly older adults at risk of falls, hip fractures, and cognitive decline from chronic benzodiazepine exposure.
Table of Contents
- Generalized Anxiety Disorder — Clinical Context
- The Andreatini 2002 GAD Trial
- Mechanism — Valerenic Acid at the Gamma-Aminobutyric Acid-A Receptor
- Compared to Benzodiazepines (Diazepam, Oxazepam, Lorazepam)
- The 1-2 Week Onset Window
- Pre-Procedural and Acute-Stress Use
- Somatic Symptoms of Anxiety (Palpitations, Tension, Gastrointestinal)
- Effect on Sympathetic Activation and HRV
- Particular Role in Older Adults
- Combination Protocols (Valerian + Lemon Balm, Valerian + Magnesium)
- Dependence, Withdrawal and Tolerance: What Is Reported
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
Generalized Anxiety Disorder — Clinical Context
Generalized anxiety disorder (GAD) is defined in DSM-5 as excessive worry occurring more days than not for at least six months, associated with three or more somatic symptoms (restlessness, fatigue, difficulty concentrating, irritability, muscle tension, sleep disturbance) and significant functional impairment. Lifetime prevalence in the U.S. is approximately 6%, with women affected at roughly twice the rate of men. The condition is chronic in the majority of patients and frequently comorbid with major depressive disorder, insomnia, irritable bowel syndrome (IBS), fibromyalgia, and chronic tension headache.
The first-line evidence-based treatments for GAD are cognitive-behavioral therapy (CBT, often with relaxation training) and selective serotonin reuptake inhibitors (SSRIs — sertraline, escitalopram, paroxetine) or serotonin-norepinephrine reuptake inhibitors (SNRIs — venlafaxine, duloxetine). Benzodiazepines are effective acutely but are generally not recommended as chronic monotherapy for GAD due to dependence concerns. Many patients with GAD seek alternatives to prescription medications for one of several reasons: side-effect intolerance with selective serotonin reuptake inhibitors (sexual dysfunction, weight gain, emotional blunting), philosophical preference for plant-based approaches, concern about dependence with benzodiazepines, or partial response on first-line agents requiring an adjunctive intervention.
Valerian, alongside chamomile (the first controlled trial of a chamomile extract in GAD was Amsterdam et al. 2009, a double-blind randomized controlled trial (RCT)), passionflower, and lemon balm, is one of the small handful of herbs tested in randomized controlled trials in formally-diagnosed GAD. For valerian there is a single such trial, and its main comparison was negative (see the next section); a 2006 Cochrane review found that this one small study gives “insufficient evidence to draw any conclusions” about valerian for anxiety disorders.
The Andreatini 2002 GAD Trial
The Andreatini 2002 trial, published in Phytotherapy Research, is the foundational randomized controlled trial of valerian for generalized anxiety disorder. Renato Andreatini and colleagues at the Federal University of Paraná in Brazil randomized 36 outpatients with GAD diagnosed by DSM-III-R criteria, after a 2-week wash-out, to one of three arms of 12 people each for four weeks: a valepotriate-rich valerian extract (mean daily dose 81.3 mg), diazepam (mean daily dose 6.5 mg), or placebo. The design was parallel, double-blind and flexible-dose, so each patient's dose was adjusted rather than fixed.
The primary outcome was change on the Hamilton Anxiety Rating Scale (HAM-A). Secondary outcomes included clinical global impression, treatment-emergent side effects, and dropout rate.
Results at 4 weeks:
- Total HAM-A — all three groups, placebo included, improved significantly from their starting scores, and there was no significant difference between the groups in that change. The authors state that this principal analysis “found negative results”, which they put down to the small number of patients per group.
- HAM-A psychic anxiety subscale (worry, anxious mood, fears, intellectual concentration) — only the diazepam and valerian groups showed a significant drop from their own starting scores. When the 2006 Cochrane review compared the groups, it found no significant difference between valerian and placebo on the psychic or the somatic (bodily symptoms) subscale.
- STAI-trait (a questionnaire of long-standing anxiety) — only the diazepam group improved significantly.
- Tolerability — no significant difference in adverse event rates among the three arms. No serious adverse events. Dropout rates were similar.
The authors concluded that valepotriates “may have a potential anxiolytic effect on the psychic symptoms of anxiety”, but that with so few patients per group the results “must be viewed as preliminary”. The 2006 Cochrane review (Miyasaka and colleagues) searched for every randomized trial of valerian in any anxiety disorder and found only this one: 36 people, no significant difference from placebo or from diazepam on the main anxiety score, and no difference among the three groups in side effects or dropouts. Its conclusion, in its own words: “there is insufficient evidence to draw any conclusions about the efficacy or safety of valerian compared with placebo or diazepam for anxiety disorders.”
Important caveats: this is a single small trial (36 patients), the extract was valepotriate-rich (most modern commercial extracts are deliberately valepotriate-low), and the diazepam dose (mean 6.5 mg/day) is at the low end of the therapeutic range for GAD. The trial would benefit from replication with a larger sample and a modern standardized valerenic-acid extract. Such a replication has not been published.
A 2020 systematic review (Shinjyo, Waddell and Green) took in 60 valerian studies with 6,894 people and ran a separate meta-analysis of 8 studies (535 people) on anxiety. It found the results inconsistent and suggested this was “possibly due to the variable quality of herbal extracts”, with more reliable effects expected from preparations of the whole root and rhizome (the underground stem). It reported no severe adverse events linked to valerian in people aged 7 to 80.
Mechanism — Valerenic Acid at the Gamma-Aminobutyric Acid-A Receptor
The mechanistic case for valerian as an anxiolytic rests primarily on valerenic acid's documented activity at the gamma-aminobutyric acid-A receptor.
The gamma-aminobutyric acid-A receptor is a pentameric ion channel typically composed of two alpha subunits, two beta subunits, and one gamma subunit. Different subunit compositions are expressed in different brain regions and mediate different functional effects:
- Alpha-1 subunit-containing receptors — primarily mediate sedation (the target of zolpidem and the predominant target of older benzodiazepines)
- Alpha-2 and alpha-3 subunit-containing receptors — primarily mediate anxiolysis
- Alpha-5 subunit-containing receptors — primarily mediate learning and memory effects (the target of cognitive carry-over)
- Beta-2 and beta-3 subunits — mediate positive allosteric modulation by anesthetic agents and several plant-derived compounds including valerenic acid
The key 2007 Khom paper, working with recombinant gamma-aminobutyric acid-A receptors expressed in Xenopus oocytes, demonstrated that valerenic acid produces positive allosteric modulation at receptors containing beta-2 or beta-3 subunits, with no effect at receptors containing beta-1 subunit. This subunit selectivity is important — it means valerenic acid does not directly compete with benzodiazepines for the alpha-gamma binding site, and the two classes can in principle be additive (their calming and sedating effects can add together when both are taken).
The subsequent 2009 Benke paper extended this work using transgenic mice in which the beta-3 subunit had been replaced with a valerenic-acid-insensitive mutant. These mice did not show the anxiolytic response to valerenic acid in the elevated plus maze and the light/dark choice test that wild-type mice did, providing direct in vivo evidence that the beta-3 subunit is required for valerenic acid's anxiolytic effect. This is one of the cleaner mechanism-to-clinical-effect links in the herbal medicine literature.
Secondary mechanisms include gamma-aminobutyric acid (GABA) transaminase (gamma-aminobutyric acid-T) inhibition (raising synaptic gamma-aminobutyric acid concentration upstream of the receptor) and adenosine A1 receptor partial agonism. The relative contribution of each mechanism to the overall clinical anxiolytic effect has not been quantified.
Compared to Benzodiazepines (Diazepam, Oxazepam, Lorazepam)
The clinical comparison between valerian and prescription benzodiazepines is best understood through the Andreatini 2002 trial (head-to-head with diazepam) and through the broader pharmacology of the two classes.
Onset. Benzodiazepines have rapid onset — alprazolam peaks at 1-2 hours, lorazepam at 2-4 hours, diazepam at 1 hour with rapid central nervous system (CNS) distribution. Acute panic attacks can be aborted within 30-60 minutes with sublingual lorazepam. Valerian has not been tested for stopping a panic attack in progress (the 2006 Cochrane review found no valerian trial in panic disorder). Its effect on chronic generalized anxiety is described as building over 1-2 weeks, although two small trials (below) found effects from single doses or a week of use in short-term stress.
Peak effect. Benzodiazepines produce a larger acute effect than valerian. A standard therapeutic dose of lorazepam (1 mg) produces a substantially larger reduction in HAM-A score within hours than 600 mg of valerian does within hours.
Duration of action with chronic use. Chronic benzodiazepine use produces tolerance — the same dose progressively loses effectiveness over months. Patients commonly require dose escalation to maintain effect, which then increases dependence risk. Valerian does not show this tolerance pattern; chronic users can maintain the same dose indefinitely with sustained effect.
Dependence. All benzodiazepines produce physical dependence with chronic daily use. Discontinuation after months of regular use requires a tapered withdrawal (typically over 2-4 months for therapeutic doses, longer for higher doses) to avoid withdrawal seizures, rebound anxiety, sleep disturbance, and autonomic instability. No physical dependence or withdrawal was reported in valerian's trials, but two published case reports describe delirium after valerian root was stopped, one of them with heart complications (Garges and colleagues, 1998; Burke and colleagues, 2020).
Cognitive effects. Chronic benzodiazepine use produces measurable cognitive impairment, particularly affecting attention, working memory, and visuospatial processing. Older adults on chronic benzodiazepines have increased fall risk, hip fracture risk, and dementia risk per multiple longitudinal studies. Valerian does not produce comparable cognitive effects.
Driving and operating machinery. Acute benzodiazepine doses produce measurable driving impairment for 4-8 hours post-dose. Valerian's acute effect on driving is minimal at standard doses but individual variability exists; the first few days of a new regimen warrant caution.
Clinical positioning. The American College of Physicians, American Academy of Family Physicians, and American Geriatrics Society guidelines all converge on the recommendation that benzodiazepines should be used for the shortest possible duration in anxiety treatment, with non-benzodiazepine alternatives preferred for chronic management. Valerian fits naturally into this framework as a tolerable chronic option for mild-to-moderate GAD in patients who would otherwise be candidates for chronic benzodiazepine prescription.
The 1-2 Week Onset Window
The 1-2 week onset window described for valerian's anxiolytic effect is drawn by analogy with its delayed-onset sleep effect, and practitioners treat it as a key point in counseling. It does not fit every study: in two small trials, valerian taken shortly before a stressor did lower anxiety — a single 100 mg dose one hour before dental surgery (Pinheiro 2014) and a single 600 mg dose of a valerian-lemon balm product before a laboratory stress test (Kennedy 2006).
Neither the Andreatini 2002 trial report nor the 2006 Cochrane review of it gives week-1 or week-2 results, so the 1-2 week window rests on the sleep literature and on practitioners' experience rather than on an anxiety trial.
The mechanism of the delayed onset is the same as for valerian's sleep effect — some combination of active metabolite accumulation, adaptive change in receptor expression with chronic gamma-aminobutyric acid-T inhibition, and the time required for any anxiolytic effect to manifest as observable change in chronic worry patterns. The cumulative-effect hypothesis is discussed in more depth on the Valerian Benefits Hub.
The doses tested in the anxiety studies were modest: the only GAD trial used a mean of 81.3 mg a day of valepotriates for 4 weeks, the dental trial a single 100 mg dose, and the laboratory-stress trial single doses of 600, 1,200 and 1,800 mg of a combined valerian-lemon balm product (where the highest dose raised anxiety rather than lowering it). Practitioners commonly describe a 2-week course before judging the effect; no anxiety trial has tested how long a course is needed.
Pre-Procedural and Acute-Stress Use
Valerian's described slow onset has led to the view that it is poorly suited to pre-procedural anxiolysis (the night-before-surgery or hour-before-dental-work indication). A small published literature has tested valerian in these settings, and the two trials below both found effects from short-term use.
The most-cited pre-procedural trial is Pinheiro et al. 2014 (Journal of Pharmacy and Bioallied Sciences), a randomized, double-blind, placebo-controlled split-mouth trial in 20 volunteers aged 17 to 31 who each had two impacted lower wisdom teeth removed, one after valerian and one after placebo. A single 100 mg dose was given one hour before each operation. By the researcher's (80%) and the surgeon's (75%) assessments, patients were calmer and more relaxed during surgery on valerian, and valerian better held systolic blood pressure and heart rate steady after surgery. The authors concluded that valerian “was more effective at controlling anxiety than a placebo” for conscious sedation in this surgery.
The Cropley 2002 trial (Phytotherapy Research) tested valerian and kava in a colour/word mental stress task in 54 healthy volunteers (18 per group: kava, valerian, or no treatment). Each was tested, took a standard dose for 7 days, and was tested again. After the week, the rise in systolic blood pressure during the stress task was significantly smaller in both the kava and valerian groups; the heart-rate rise fell in the valerian group but not in the kava group; and both groups reported feeling less pressure. The control group did not change.
Options used for anxiety before a procedure include:
- Pharmacologic — short-acting benzodiazepine (e.g., midazolam intravenous (IV), into a vein, or lorazepam sublingual, dissolved under the tongue) administered by the proceduralist
- Behavioral — box-breathing (4-second inhale, 4-second hold, 4-second exhale, 4-second hold), progressive muscle relaxation, music with headphones
- Herbal acute — practitioners describe kava 200-300 mg of standardized extract 30-60 minutes pre-procedure (kava is not legally sold everywhere and carries liver-safety concerns); valerian itself was given as a single 100 mg dose one hour before surgery in the Pinheiro trial
- Herbal chronic preceding — when someone has taken valerian as a chronic anxiolytic for weeks before a procedure, practitioners usually leave the regimen unchanged on the day itself (see Cautions for the separate question of stopping before surgery under anesthesia).
Somatic Symptoms of Anxiety (Palpitations, Tension, Gastrointestinal)
Generalized anxiety disorder includes a substantial somatic-symptom burden that often dominates the clinical presentation: muscle tension (particularly in the trapezius, neck, and jaw), tension headaches, gastrointestinal symptoms (cramping, diarrhea or constipation, nausea), and cardiovascular symptoms (palpitations, sensation of a pounding heart, occasional ectopy). Many patients seek treatment not for the worry itself but for one of these somatic manifestations.
Valerian's antispasmodic activity on smooth muscle (discussed in detail on the Muscle Relaxation page) means it can address several of the somatic symptoms simultaneously with its central anxiolytic effect. This is part of why valerian has been used historically for "nervous indigestion" and tension headache alongside formal anxiety indications. The dual central and peripheral action is one of valerian's clinical strengths.
For the specific somatic-symptom patterns:
- Muscle tension and tension headache — valerian's smooth-muscle and (to a lesser extent) skeletal-muscle relaxation may provide modest direct relief; combination with magnesium glycinate often produces additive benefit. See our Migraine page.
- Gastrointestinal symptoms — valerian's antispasmodic effect on intestinal smooth muscle can reduce the cramping and altered motility of anxiety-related irritable bowel syndrome; combination with peppermint oil (the most-evidenced antispasmodic for irritable bowel syndrome) is reasonable.
- Palpitations — if the palpitations are driven by sympathetic over-activation in chronic GAD, valerian's central anxiolytic effect may reduce them; see also our Heart Palpitations page for the broader differential including cardiac causes that need rule-out before assuming anxiety etiology.
- Sleep disturbance — the sleep effect overlaps with the anxiolytic effect; see the Sleep Quality page.
Effect on Sympathetic Activation and HRV
A handful of trials have examined valerian's effect on objective autonomic measures. Heart rate variability (HRV), a marker of parasympathetic tone, is reduced in chronic anxiety states; restoration of HRV is increasingly used as a non-subjective outcome in anxiety trials.
The Cropley et al. 2002 trial measured cardiovascular responses to a colour/word mental stress task in 54 healthy volunteers before and after 7 days of valerian, kava, or no treatment. After the week of valerian, the stress-induced rise in systolic blood pressure and in heart rate were both significantly smaller; diastolic blood pressure did not change. Kava reduced the systolic rise but not the heart-rate rise. HRV itself was not measured.
The autonomic data, while limited, support the model that valerian's anxiolytic effect operates centrally (on gamma-aminobutyric acid-A receptors in the limbic system and prefrontal cortex) rather than through direct peripheral autonomic blockade. This contrasts with beta-blockers (propranolol), which work through direct peripheral beta-adrenergic blockade and produce immediate reduction in heart rate, tremor, and palpitations without affecting central worry.
Particular Role in Older Adults
Valerian has a particularly compelling clinical positioning in older adults (typically defined as age 65 or above). The American Geriatrics Society Beers Criteria, the standard reference for medications to avoid in older adults, explicitly recommends against routine benzodiazepine use in this population due to increased risk of:
- Falls and hip fractures (benzodiazepines increase fall risk by approximately 50% in older adults)
- Cognitive impairment and dementia (associations with chronic benzodiazepine use in multiple longitudinal cohorts)
- Delirium during hospital stays
- Motor vehicle accidents
- Daytime sedation and impaired driving performance
Anxiety in older adults is nonetheless common (prevalence around 10-15%) and undertreated. Many older patients who would benefit from anxiety treatment refuse selective serotonin reuptake inhibitors due to side-effect concerns and are appropriately steered away from benzodiazepines by current guidelines. Valerian fits naturally into this clinical gap as a tolerable chronic option with no fall-risk signal and no cognitive-impairment signal reported, and no withdrawal reported in its trials (the two case reports of delirium after stopping valerian root are described below).
None of the anxiety trials on this page studied older adults or set a dose for them; the 2020 review of 60 valerian studies reported no severe adverse events in people aged 7 to 80. Dose adjustments are not typically required based on renal or hepatic function for valerian as they are for benzodiazepines.
For the related discussion of falls and benzodiazepine risk in older adults, see the Insomnia page.
Combination Protocols (Valerian + Lemon Balm, Valerian + Magnesium)
Several traditional and modern combinations leverage additive low-affinity mechanisms.
Valerian + lemon balm (Melissa officinalis). The Kennedy et al. 2006 trial tested a valerian-lemon balm combination in a laboratory-induced anxiety paradigm in healthy volunteers; 24 volunteers each took single doses of 600, 1,200 and 1,800 mg and a placebo on separate days. The 600 mg dose reduced the rise in anxiety ratings caused by the stress test, but the 1,800 mg dose increased anxiety (significantly in one testing session), all three doses worsened performance on the Stroop task (a word-colour attention test), and the two lower doses lowered the overall test-battery score. The Cases et al. 2011 pilot study tested a lemon balm (Melissa officinalis) leaf extract on its own, not a combination with valerian: in an open-label 15-day study of 20 stressed volunteers with mild-to-moderate anxiety and sleep problems, clinician-rated anxiety fell by 18% and insomnia by 42%, with no placebo group. The Mueller and Klement 2006 study gave the valerian-lemon balm combination to 918 children under 12 with restlessness and sleep problems in an open (uncontrolled) multicentre study; investigators and parents reported improvement, and tolerability was judged good in 96.7% of the children. See our Lemon Balm page.
Valerian + passionflower (Passiflora incarnata). Passionflower contains chrysin and related flavonoids with gamma-aminobutyric acid-A modulating activity. Combination products are widely sold but have less randomized controlled trial evidence than the valerian-lemon balm pairing. Passionflower alone has positive randomized controlled trial data in pre-procedural anxiety. See our Passionflower page.
Valerian + magnesium glycinate. Magnesium glycinate at 200-400 mg twice daily is widely combined with valerian for patients with mixed anxiety, muscle tension, and sleep disturbance. The mechanisms are complementary (magnesium acts at the N-methyl-D-aspartate (NMDA) receptor and as a calcium-channel modulator, valerian at gamma-aminobutyric acid-A and gamma-aminobutyric acid-T). See our Magnesium Glycinate page.
Valerian + L-theanine. L-theanine, an amino acid found in green tea, increases alpha-wave electroencephalogram (EEG) activity associated with relaxed alertness. The combination of valerian (sedative-anxiolytic) with L-theanine (calming without sedation) is commonly used by patients who need daytime anxiety control without sedation, with valerian dose-adjusted lower to avoid daytime drowsiness.
Valerian + ashwagandha. Ashwagandha (an adaptogen with its own anxiolytic activity through different mechanisms involving cortisol modulation) combined with valerian is particularly useful for patients with high cortisol-driven anxiety (hypothalamic-pituitary-adrenal-axis dysregulation), where valerian provides GABAergic calming and ashwagandha addresses the upstream stress-response activation. See our Ashwagandha page.
Dependence, Withdrawal and Tolerance: What Is Reported
The most important pharmacologic difference between valerian and prescription benzodiazepines, from a chronic-use safety perspective, is that no physical dependence, tolerance, or withdrawal has been reported in valerian's clinical trials (no withdrawal phenomena in trial participants who discontinued valerian after weeks or months of dosing). Two published case reports are the exception: a 1998 report in JAMA described heart complications and delirium associated with stopping valerian root (Garges, Varia and Doraiswamy), and a 2020 report in Psychosomatics described delirium after withdrawal from valerian root (Burke and colleagues).
The mechanistic explanation is that the low-affinity, multi-mechanism profile of valerian does not produce the receptor saturation that drives tolerance in benzodiazepines. Chronic high-affinity occupancy of the benzodiazepine binding site by alprazolam or lorazepam triggers compensatory downregulation of gamma-aminobutyric acid-A receptor expression, which is the substrate of both tolerance (need for higher dose for same effect) and withdrawal (when the drug is removed, the downregulated gamma-aminobutyric acid-A system produces rebound central nervous system hyperexcitability). Valerenic acid's low-affinity, partial allosteric modulation does not occupy the receptor to the degree required to trigger this compensatory response.
The clinical implications are substantial:
- Trial participants stopped valerian without a taper and no withdrawal was reported; the two case reports above are the documented exceptions, both describing delirium after valerian root was stopped
- Patients do not need to escalate dose over time to maintain effect
- Travel disruption to dosing (running out, forgetting a few days) is not reported to produce withdrawal anxiety or insomnia
- Combining or switching with other anxiolytic interventions is not complicated by withdrawal management
This safety profile is the strongest argument for valerian as a chronic-use option versus prescription benzodiazepines for patients with mild-to-moderate chronic anxiety, even acknowledging that benzodiazepines produce a larger acute effect.
Cautions and Drug Interactions
- Acute panic is not a valerian indication. Valerian has not been tested for stopping a panic attack in progress. Acute episodes are treated with breathing techniques, prescribed benzodiazepines, and exposure therapy techniques; valerian has been studied for ongoing anxiety and short-term stress, not for acute rescue.
- Central nervous system depressant interactions. Additive sedative effect with alcohol, benzodiazepines, opioids, Z-drugs, sedating antidepressants: the drowsiness from each adds together.
- Driving and operating machinery. The first few days of a new valerian regimen warrant caution with driving and machinery. After dose tolerance is established (typically within a week), most patients have no measurable daytime impairment at standard doses.
- Pregnancy and lactation. Both the WHO and the European Medicines Agency (EMA) recommend avoidance in pregnancy and lactation due to insufficient data, not due to documented harm. Generalized anxiety in pregnancy is commonly treated with cognitive behavioral therapy and (when needed) selective serotonin reuptake inhibitors that have favorable pregnancy data such as sertraline.
- Anesthesia. Valerian's sedative effect may add to that of anesthetic agents, which is why pre-surgery advice commonly lists stopping it at least 1 week before elective surgery. Because of the withdrawal case reports above, the surgical team knowing about long-term use matters too.
- CYP450 interactions. In vitro evidence of weak cytochrome P450 3A4 (CYP3A4) inhibition. Cyclosporine, tacrolimus, certain calcium channel blockers and certain statins are broken down by cytochrome P450 3A4 and have a narrow margin between an effective and a harmful blood level, so any slowing of that breakdown matters most with these drugs.
- Bipolar disorder. Patients with bipolar disorder are at risk of treatment-emergent affective switching with many anxiolytic and antidepressant interventions. Valerian has not been specifically studied in bipolar populations; bipolar disorder is treated with bipolar-specific pharmacology (mood stabilizers), and valerian alone has not been tested as a treatment for it.
- Failure to improve at 2 weeks — reassess for primary disorder. Patients who do not improve on valerian for "anxiety" at 2 weeks may have a primary disorder other than GAD (panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety, depression with anxiety features) that has its own targeted treatments; clinicians usually re-examine the diagnosis before labelling the anxiety "treatment-resistant."
Key Research Papers
- Andreatini R, Sartori VA, Seabra ML, Leite JR (2002). Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytotherapy Research. — PubMed PMID: 12410546
- Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S (2007). Valerenic acid potentiates and inhibits GABA-A receptors: molecular mechanism and subunit specificity. Neuropharmacology. — PubMed PMID: 17585957
- Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Mohler H (2009). GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid. Neuropharmacology. — PubMed PMID: 18602406
- Kennedy DO, Little W, Haskell CF, Scholey AB (2006). Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytotherapy Research. 2006;20(2):96-102. — PubMed PMID: 16444660
- Cases J, Ibarra A, Feuillere N, Roller M, Sukkar SG (2011). Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean Journal of Nutrition and Metabolism. 2011;4(3):211-218. — PubMed PMID: 22207903
- Cropley M, Cave Z, Ellis J, Middleton RW (2002). Effect of kava and valerian on human physiological and psychological responses to mental stress. Phytotherapy Research. — PubMed PMID: 11807960
- Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH (2010). Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine. — PubMed PMID: 20042323
- Müller SF, Klement S (2006). A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine. 2006;13(6):383-387. — PubMed PMID: 16487692
- Miyasaka LS, Atallah AN, Soares BG (2006). Valerian for anxiety disorders. Cochrane Database of Systematic Reviews. — PubMed PMID: 17054208
- Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A (2011). Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. European Neuropsychopharmacology. — PubMed PMID: 21601431
- Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J (2009). A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology. — PubMed PMID: 19593179
- Pinheiro ML, Alcântara CE, de Moraes M, de Andrade ED (2014). Valeriana officinalis L. for conscious sedation of patients submitted to impacted lower third molar surgery: a randomized, double-blind, placebo-controlled split-mouth study. Journal of Pharmacy and Bioallied Sciences. 2014;6(2):109-114. — PubMed PMID: 24741279
- Shinjyo N, Waddell G, Green J (2020). Valerian root in treating sleep problems and associated disorders — a systematic review and meta-analysis. Journal of Evidence-Based Integrative Medicine. 2020;25:2515690X20967323. — PubMed PMID: 33086877
- Garges HP, Varia I, Doraiswamy PM (1998). Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998;280(18):1566-1567. — PubMed PMID: 9820254
- Burke H, Jiang S, Chatham P, Stern TA (2020). Delirium after withdrawal from valerian root: a case report. Psychosomatics. 2020;61(6):787-790. — PubMed PMID: 32576405
PubMed Topic Searches
Connections
- All Herbs
- Valerian Overview
- Valerian Benefits Hub
- Valerian for Sleep
- Valerian for Muscle Relaxation
- Valerian for Menstrual Cramps
- Passionflower
- Lemon Balm
- Chamomile
- Kava
- Ashwagandha
- Rhodiola Rosea
- Magnesium
- Magnesium Glycinate
- Anxiety
- Depression
- Insomnia
- Heart Palpitations
- Natural Anxiety Relief
- Stress Management
- History